An ongoing clinical trial will evaluate the safety and tolerability of a CXCR1/CXCR2 inhibitor in combination with anti-PD1 as a maintenance therapy in patients with metastatic pancreatic ductal adenocarcinoma and will also assess the immunophenotypic and stromal changes to the tumor microenvironment after treatment (NCT04477343). Here, PDCD1 is linked to neoplasm.